35207-08-0

Basic information

• Product Name: N-(aminocarbonyl)benzenesulphonamide
• Synonyms: N-(aminocarbonyl)benzenesulphonamide;N-(Phenylsulfonyl)urea;N-Carbamoylbenzenesulfonamide;benzenesulfonamide, N-(aminocarbonyl)-
• CAS NO: 35207-08-0
• Molecular Formula: C₇H₈N₂O₃S
• Molecular Weight: 200.21502
• EINECS: 252-441-5
• Mol File: 35207-08-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 367.9°Cat760mmHg
• Flash Point: 176.3°C
• Appearance: /
• Density: 1.421g/cm³
• Vapor Pressure: 4.63E-06mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: N-(aminocarbonyl)benzenesulphonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(aminocarbonyl)benzenesulphonamide(35207-08-0)
• EPA Substance Registry System: N-(aminocarbonyl)benzenesulphonamide(35207-08-0)

Safety Data

• Hazardous Substances Data: 35207-08-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H8N2O3S/c8-7(10)9-13(11,12)6-4-2-1-3-5-6/h1-5H,(H3,8,9,10)

Upstream product

• 590-28-3 potassium cyanate 
• 98-10-2 benzenesulfonamide 
• 854695-24-2 O-ethyl-N-benzenesulfonyl-isourea 
• 2845-62-7 benzenesulphonyl isocyanate 
• 50881-53-3 N-Chlorsulfonyl-N'-phenylsulfonylharnstoff 
• 54459-36-8 C₁₀H₁₆N₂O₃SSi 
• 98-09-9 benzenesulfonyl chloride 
• 57-13-6 urea 
• 54459-35-7 C₁₃H₂₄N₂O₃SSi₂ 

Downstream Products

• 2619-42-3 N,N-bis(2-cyanoethyl)benzenesulfonamide 
• 102924-54-9 Diphensaeure-bis-(benzolsulfonylcarbamoyl-amid) 
• 708275-02-9 1-(phenylsulfonyl)-3-(2,2-dimethoxyethyl)urea 
• 859721-81-6 2-(phenylsulfonyl)-1-[4-(trifluoromethyl)phenyl]ethan-1-one 
• 708275-06-3 1-(phenylsulfonyl)-(1H,3H)-imidazol-2-one 

Relevant articles and documents

-

-

Synthesis and biological evaluation of sulfonamidooxazoles and β-keto sulfones: Selective inhibitors of 11β-hydroxysteroid dehydrogenase type I

The design, synthesis, and biological evaluation of arylsulfonamidooxazoles as 11β-HSD1 inhibitors and the serendipitous discovery of β-keto sulfones as potent 11β-HSD1 inhibitors are described here. These two classes of compounds are not active against 11β-HSD2 and therefore may have significant therapeutic potential for metabolic syndrome, type 2 diabetes and related metabolic dysfunctions.